AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
SECUKINUMAB
6 registrations across 3 African markets— 5 active
Markets with SECUKINUMAB
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| COSENTYX 150 mg/ml | 🇿🇦South Africa | Novartis South Africa (Pty) Ltd | active | Jun 2030 |
| SCAPHO 150 mg | 🇿🇦South Africa | Novartis South Africa (Pty) Ltd | active | Oct 2029 |
| COSENTYX 300 mg/2 ml SOLUTION FOR INJECTION | 🇿🇦South Africa | Novartis South Africa (Pty) Ltd | active | Sept 2027 |
| COSENTYX 75 mg/0,5 ml SOLUTION FOR INJECTION | 🇿🇦South Africa | Novartis South Africa (Pty) Ltd | active | Sept 2027 |
| FRAIZERON, secukinumab 150mg Powder For Injection | 🇰🇪Kenya | Novartis Overseas Investment AG | active | Sept 2026 |
| COSENTYX SensoReady Solution injectable / 150 MG/ML | 🇹🇳Tunisia | NOVARTIS PHARMA SCHWEIZ AG | expired | Oct 2023 |
SECUKINUMAB in Africa — Regulatory Overview
SECUKINUMAB is registered across 3 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Kenya, Tunisia. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 5 (83%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.